# A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

> **NCT02597933** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 580 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02597933
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-12
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-11-28
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597933, "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02597933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*